Intranasal Naloxone
(NS-001)
Access to naloxone is a priority for reducing opioid deaths. Intranasal Naloxone aimed at assisting in acute emergency situations like opioid overdose.
Medical need
In 2017 ~72000 overdose death in the USA~42000 from opioids.
Regulatory requirements
Bioequivalence study –”equal or better”
Nasus pharma presented clinical results at Fourth Annual
ASPN Conference, July 14-17, Miami Beach
Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan® – READ MORE
Pilot Study
The peak systemic exposure was approximately
1.6 fold higher
The partial AUC0-4 minutes was approximately
7 fold higher
The partial AUC0-10 minutes was approximate
4 fold higher
The partial AUC10-30 minutes was approximate
1.6 fold higher
The total systemic exposure was approximate
1.26 fold higher
The median Tmax occurred approximately
5 minutes earlier